COMMUNICATION:
Cleavage of PITSLRE Kinases by ICE/CASP-1 and CPP32/CASP-3 during Apoptosis Induced by Tumor Necrosis Factor*

(Received for publication, November 8, 1996, and in revised form, February 7, 1997)

Rudi Beyaert Dagger , Vincent J. Kidd §, Sigrid Cornelis Dagger , Marc Van de Craen , Geertrui Denecker , Jill M. Lahti §, Rajagopal Gururajan §, Peter Vandenabeele Dagger and Walter Fiers par

From the Laboratory of Molecular Biology, Flanders Interuniversity Institute for Biotechnology and University of Ghent, B-9000 Ghent, Belgium and the § Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Emerging evidence suggests that multiple aspartate-specific cysteine proteases (caspases (CASPs)) play a crucial role in programmed cell death. Many cellular proteins have been identified as their substrates and serve as markers to assay the activation of CASPs during the death process. However, no substrate has yet been unambiguously identified as an effector molecule in apoptosis. PITSLRE kinases are a superfamily of Cdc2-like kinases that have been implicated in apoptotic signaling and tumorigenesis. In this paper we report that tumor necrosis factor (TNF)-mediated apoptosis is associated with a CrmA- and Bcl-2-inhibitable cleavage of PITSLRE kinases, indicating a role for CASPs. Testing of seven murine CASPs for their ability to cleave p110 PITSLRE kinase alpha 2-1 in vitro revealed that only CASP-1 (ICE (interleukin-1beta -converting enzyme)) and CASP-3 (CPP32) were able to produce the same 43-kDa cleavage product as observed in cells undergoing TNF-induced apoptosis. Mutational analysis revealed that cleavage of p110 PITSLRE kinase alpha 2-1 occurred at Asp393 within the sequence YVPDS, which is similar to that involved in the CASP-1-mediated cleavage of prointerleukin-1beta . TNF-induced proteolysis of PITSLRE kinases was still observed in fibroblasts from CASP-10/0 mice. These data implicate CASP-3 as a potentially important CASP family protease responsible for the cleavage of PITSLRE kinases during TNF-induced apoptosis.


INTRODUCTION

Apoptosis is a fundamental process for normal development of multicellular organisms and is involved in the regulation of the immune system, normal morphogenesis, and maintenance of homeostasis (1). Aspartate-specific cysteine proteases belonging to the interleukin-1beta -converting enzyme (ICE)1 family, recently renamed the caspase (CASP) family (2), have been implicated as principal effectors of apoptosis, presumably by their proteolytic action on specific targets, including members of the ICE-related protease family themselves, poly(ADP-ribose) polymerase, DNA-dependent protein kinase, the 70-kDa small U1 ribonucleoprotein, lamins, protein kinase Cdelta , D4-GDP dissociation inhibitor, and various components of the cytoskeleton (3, 4). Many of these proteins are likely to be involved in the morphological and biochemical changes that accompany apoptosis, or in aspects of DNA damage sensing and repair, and are used as markers to assay the activation of CASPs during the death process. However, no substrate has yet been unambiguously identified as a downstream effector molecule in apoptosis.

PITSLRE kinases are a superfamily of protein kinases related to the master mitotic protein kinase Cdc2 (4-6). Ectopic expression of the smallest member of this superfamily has previously been shown to induce apoptosis (5). In addition, deletion of the PITSLRE gene complex and complete loss of expression of specific isoforms occur in many neuroblastoma cell lines and is frequently observed in human cancers (8-10). Induction of apoptosis via the Fas receptor in human T cells has recently been shown to be correlated with proteolysis and increased activity of PITSLRE kinases (7). Triggering of Fas or the related TNF receptor is known to induce the activation of several CASPs (3, 4). Hence we examined the possibility that PITSLRE kinases are substrates for CASP-1 (ICE) and six other members of the murine CASP family in vitro as well as in vivo and demonstrate that CASP-3 (CPP32) is likely to be a crucial CASP responsible for PITSLRE kinase cleavage during TNF-induced apoptosis.


MATERIALS AND METHODS

Cell Lines and Transfections

All cell lines were cultured in appropriate media using standard tissue culture conditions. PC60p55p75 is a rodent T cell hybridoma that has been transfected with the p55 and p75 human TNF receptors (11). HeLaH21 is a human cervix carcinoma. Transfection, isolation, and characterization of Bcl-2-expressing PC60p55p75 cells were described previously (11). HeLaH21 cells expressing CrmA were obtained by transfection with 30 µg of pCAGGS-CrmA and 1 µg of pSV2neo using the calcium phosphate-DNA co-precipitation method and selecting G418-resistant transformants by culturing cells in medium containing 500 µg ml-1 G418 for 3 weeks. pCAGGS-CrmA was constructed by inserting the cowpox virus DNA fragment encoding CrmA, provided by Dr. J. Pickup (12), into the mammalian expression vector pCAGGS (13). CrmA expression was confirmed by Western blotting. Embryonic fibroblasts were prepared from wild-type and CASP-10/0 mice as described previously (14).

Cell Lysis and Immunoblotting

These were performed essentially as described previously (6, 7). PITSLRE kinases were detected using antibody P2N100 directed against the first 50 amino acids of the p110 isoforms or antibody GN1 directed against the first 72 amino acids of p58 PITSLRE kinase beta 1 (6). ECL (Amersham Life Science, Amersham, United Kingdom) was used for visualization.

Protease Assays

p110 PITSLRE kinase alpha 2-1 and proIL-1beta cDNAs were subcloned into the pGEM11Zf(+) plasmid (Promega, Madison, WI) behind the T7 and SP6 promoter, respectively, using routine recombinant DNA techniques. 35S-Labeled proIL-1beta and p110 PITSLRE kinase alpha 2-1 were prepared by the in vitro coupled transcription-translation reticulocyte lysate system (Promega) with SP6 and T7 polymerase, respectively, and incubated for 70 min at 30 °C with either purified recombinant human CASP-1 (a gift from Drs. N. Thornberry (Merck Research Laboratories) and R. Talanian (BASF Bioresearch Corp., Worcester, MA)), murine CASP-1 or CASP-3, or crude cell extracts from Escherichia coli transformed with different murine CASP expression plasmids, in a total volume of 25 µl of CASP reaction buffer containing 10 mM HEPES, pH 7.5, 2 mM EDTA, 0.1% CHAPS, 10 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 20 µg ml-1 leupeptin, and 10 µg ml-1 aprotinin. In some experiments, p110 PITSLRE kinase was first purified from the reticulocyte lysate by immunoprecipitation with antibody GN1 as described (6). Reactions were stopped by the addition of SDS-PAGE sample buffer. Cleavage products were analyzed by SDS-PAGE and fluorography.

Site-directed Mutagenesis

The p110 PITSLRE kinase alpha 2-1 D393A mutant was generated by PCR methodology using the mutagenic oligonucleotide primer TTCGACCGATCCGGGGA and a kit from CLONTECH. The presence of the introduced mutation (underlined) and fidelity of PCR replication were confirmed by sequence analysis.

Cell Death Assays

Cell death was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method (15), or in the case of PC60 cells, by propidium iodide uptake, as described previously (11).

Bacterial Expression and Purification of Murine CASPs

The full-length cDNA clones of murine, CASP-1, CASP-2, CASP-3, CASP-6, CASP-7, CASP-11, and CASP-12 (16), were used as a template for classical PCR amplification with Vent polymerase and primers designed to generate CASPs lacking the N-terminal prodomain and appending a 10-amino acid Strep-tag to the C terminus. The resulting products were cloned into the bacterial expression vector pLT10TH downstream of the His tag and transformed in E. coli strain MC1061pT7POL23 (17). Empty pLT10TH was used as a negative control. Exponentially growing E. coli at 28 °C were induced by a temperature shift to 42 °C. Bacterial extracts were prepared by sonication in CASP reaction buffer and either used as active enzyme preparations for in vitro cleavage experiments or further purified by TALON immobilized metal affinity chromatography (CLONTECH) and elution with 20 mM Tris-HCl, pH 7.5, 100 mM imidazole, 50 mM NaCl, 10% glycerol, and 1 mM glutathione. All CASPs were expressed at approximately equal levels, except for CASP-7 which was about 5-fold higher.


RESULTS AND DISCUSSION

We first studied the cleavage of PITSLRE kinases and the role of CASPs in the killing of a rodent PC60p55p75 T cell hybridoma by human TNF. Expression and proteolysis of PITSLRE kinases were examined by Western blotting using PITSLRE kinase-specific antibodies P2N100 and GN1 (6, 7). In the cells studied, the former recognized the p110 PITSLRE kinase alpha 2 and beta 2 isoforms (Fig. 1A), while the latter reacted with a p90 PITSLRE kinase isoform, which has been tentatively identified as an alternatively spliced PITSLRE kinase isoform lacking much of exon 2, but containing all other exons (6),2 and a 170-kDa protein, which is presumably another unknown PITSLRE kinase isoform (Fig. 1B). The PITSLRE kinase alpha 1 (p65) and beta 1 (p58) isoforms could not be detected and are presumably not present in the cells used. Following treatment of PC60p55p75 cells with TNF, the p110 PITSLRE kinase isoform was cleaved to fragments of 60 and 43 kDa and a minor 52-kDa product (Fig. 1A). These processing products seemed to be very unstable, because they were only detectable when p110 cleavage was still incomplete and after long exposure times of the blots. In parallel, the p170 isoform was cleaved to a 130-kDa protein, which accumulated with increasing TNF exposure times, while the p90 isoform remained unaffected (Fig. 1B). Proteolysis of PITSLRE kinases was already detectable after 2-h TNF treatment, slightly preceding the onset of TNF-induced apoptosis. Similar results were obtained in HeLa cells that had been treated with anti-Fas antibody or TNF (data not shown). Nonspecific proteolysis could be excluded by the fact that several other proteins were not degraded (data not shown). As mentioned above, the p90 PITSLRE kinase isoform lacks exon 2, corresponding to amino acids 375-415 of the PITSLRE kinase alpha 2-1 110-kDa isoform. This region of the protein contains a putative cleavage site for proteases of the CASP family (YVPD393down-arrow S). The observation that the p90 PITSLRE kinase isoform, in contrast to the p110 and p170 PITSLRE kinase isoforms, was not cleaved after TNF treatment, suggests a possible role for CASPs in TNF-induced cleavage of the p110 and p170 PITSLRE kinase isoforms. The latter hypothesis was further substantiated by investigating the effect of TNF in cells stably transfected with either the human bcl-2 or cowpox virus crmA gene, which encode proteins known to act as upstream (18) or direct (12) inhibitors, respectively, of at least some CASPs. Overexpression of these genes has been shown previously to protect cells against TNF-induced apoptosis (11, 19, 20). Both CrmA and Bcl-2 expression completely inhibited the TNF-induced cleavage of PITSLRE kinases as well as cell death (Fig. 2). Similarly, pretreatment of cells with the CASP-specific inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Ref. 4; Enzyme Systems Products, Dublin, CA), in contrast with inhibitors of granzyme B, cathepsin B, serine, and cysteine proteases, completely protected cells from TNF-induced apoptosis and PITSLRE kinase cleavage (data not shown). These results further indicate a role for CASPs in the cleavage of PITSLRE kinases during the TNF-induced cell death pathway.


Fig. 1. Cleavage of PITSLRE kinases after TNF treatment. PC60p55p75 cells were treated with 10,000 IU ml-1 human TNF. Cell lysates were prepared at different time points and resolved by 8% SDS-PAGE. Expression and cleavage of PITSLRE kinases was assessed by Western blotting and detection with P2N100 (A) and GN1 (B) antibodies, respectively. Positions of the uncleaved substrates along with their cleavage products are indicated by closed and open arrowheads, respectively. Cell death at the corresponding time points is indicated at the bottom of each lane and represents the mean of triplicate samples with an S.D. <10%.
[View Larger Version of this Image (28K GIF file)]


Fig. 2. Cleavage of PITSLRE kinases is inhibited by Bcl-2 or CrmA expression. A, two representative neomycin-resistant PC60p55p75 cell clones, expressing either the neo gene alone or in combination with the bcl-2 gene, were left untreated or treated with 10,000 IU ml-1 human TNF for 5 h. Expression and cleavage of PITSLRE kinases were assessed by Western blotting with P2N100 (upper panel) and GN1 (lower panel) antibodies, respectively. Cell death is indicated at the bottom of each lane and represents the mean of triplicate samples with an S.D. <10%. B, two representative HeLa cell clones, expressing either the neo gene alone or in combination with the crmA gene, were untreated or treated with 10,000 IU ml-1 human TNF in the presence of 1 µg ml-1 actinomycin D for 6 h and analyzed as described above.
[View Larger Version of this Image (41K GIF file)]

In the human system, the CASP family comprises seven different members that share a conserved QACRG pentapeptide containing the active site cysteine (2-4). More recently, three additional CASPs have been described, viz. CASP-8 (MACH = FLICE = Mch5; Refs. 21-23), CASP-9 (ICE-LAP6; Ref. 24), and CASP-10 (Mch4; Ref. 21). These differ from the other CASPs by a nonconservative substitution in the active site QACRG pentapeptide, and the presence of a FADD-like effector domain in the case of CASP-8 and CASP-10. In mice, only the cloning of CASP-1 (ICE), CASP-2 (NEDD-2 = human Ich1) and CASP-11 (Ich3) has been reported so far (2-4, 25). We have recently isolated and characterized seven murine CASPs containing the conserved QACRG box (16)3: CASP-1 (ICE), CASP-2 (Ich1), CASP-3 (CPP32, Yama, or apopain), CASP-6 (Mch2), CASP-7 (Mch3, ICE-LAP3, or CMH-1), CASP-11 (presumably the murine homolog of human CASP-4, TX, Ich2, or ICErel-II), and CASP-12 (related but presumably not homologous to human CASP-5 or ICErelIII). To analyze whether one of these CASPs can directly cleave PITSLRE kinases, we treated in vitro translated p110 PITSLRE kinase alpha 2-1 with crude cell extracts of bacteria expressing the specific murine CASPs. Interestingly, CASP-1 and CASP-3 were the only CASPs that could cleave p110 PITSLRE kinase to a 43-kDa processed product (Fig. 3). In some experiments, weak 60- and 80-kDa cleavage products could also be observed (see also Fig. 4). The size of the 43- and 60-kDa PITSLRE kinase cleavage products corresponds to the size of the protein bands that were observed after TNF-induced cleavage of the p110 PITSLRE kinase in vivo (Fig. 1A), further suggesting that the latter is mediated by CASP-1 or CASP-3. None of the other CASPs displayed any effect on the PITSLRE kinase, although they were all found, except CASP-12 (which was nevertheless able to induce apoptosis after transfection; Ref. 16)3, to hydrolyze the synthetic peptide substrates acetyl-Asp-Glu-Val-Asp-aminomethylcoumarin (DEVD-AMC) and/or acetyl-Tyr-Val-Ala-Asp-aminomethylcoumarin (YVAD-AMC): CASP-1, CASP-2, CASP-6, CASP-7, and CASP-11 were about 2,000, 700, 4,000, 100, and 2,000 times, respectively, less active than CASP-3 on DEVD-AMC; CASP-1 and CASP-3 were the only enzymes found to be active on YVAD-AMC, CASP-3 being about 25 times less active than CASP-1 (data not shown). Similar results were obtained when purified, in vitro translated p110 PITSLRE kinase and purified recombinant CASPs were used, excluding any contribution of reticulocyte or bacterial proteases that may become activated when CASPs are present (see also Fig. 4).


Fig. 3. Effect of CASPs on p110 PITSLRE kinase in vitro. 35S-Labeled p110 PITSLRE kinase alpha 2-1 was incubated with cell extracts prepared from E. coli cells expressing the indicated murine CASPs. Cleavage products were analyzed by SDS-PAGE and fluorography. The position of the uncleaved p110 PITSLRE kinase along with the 43-kDa processing product is indicated by a closed and open arrowhead, respectively. Data for CASP-12 are not shown, since this enzyme did not exert activity on any of the substrates tested (see Footnote 3).
[View Larger Version of this Image (39K GIF file)]


Fig. 4. Comparison of the cleavage of proIL-1beta , p110 PITSLRE kinase wild-type and p110 PITSLRE kinase D393A by purified CASP-1 and CASP-3 in vitro. Purified 35S-labeled proIL-1beta (A), or purified p110 PITSLRE kinase alpha 2 wild-type and p110 PITSLRE kinase D393A (B, C), were incubated at an equivalent substrate concentration with the indicated concentrations of purified recombinant CASP-1 (A, B) or CASP-3 (C) for 70 min at 30 °C. 1 ng of CASP-1 or CASP-3 corresponds to 1.5 units or 0.06 unit, respectively, 1 unit being defined as the amount of enzyme required to generate 1 pmol of AMC/min at 25 °C using saturating levels of the fluorogenic substrate YVAD-AMC (26). Cleavage of substrates was analyzed by SDS-PAGE and fluorography. Positions of the uncleaved substrates along with their processed products are indicated by closed and open arrowheads, respectively.
[View Larger Version of this Image (60K GIF file)]

Examination of the amino acid sequence of the p110 PITSLRE kinase revealed that the 43-kDa protein generated upon incubation with CASP-1 or CASP-3 could be generated by cleavage at the sequence YVPD393down-arrow S, which is very similar to the YVHDdown-arrow A cleavage site for CASP-1 in proIL-1beta (26) and which conforms to the specific hydrolysis of YVAD-AMC by CASP-1 and CASP-3 as described above. Indeed, in vitro translated proIL-1beta and p110 PITSLRE kinase alpha 2 were cleaved with similar efficiency by purified CASP-1, requiring a minimal CASP-1 concentration of only 0.25 ng (Fig. 4, A and B). PITSLRE kinase cleavage by CASP-3 required about 25 times higher concentrations than CASP-1 (Fig. 4C). Moreover, a p110 PITSLRE kinase, in which Asp393 in the sequence YVPDdown-arrow S had been mutated to Ala, was no longer cleaved by CASP-1 or CASP-3 (Fig. 4, B and 4C), although some residual nonspecific cleavage resulting in a 43-kDa degradation product could still be observed at microgram concentrations of CASP-3 (data not shown). These data, together with the observation that a p90 PITSLRE kinase isoform lacking a region containing the YVPDdown-arrow S sequence is not cleaved in cells undergoing TNF-induced apoptosis (see above and Fig. 1A), demonstrate that p110 PITSLRE kinase is efficiently cleaved by CASP-1 and CASP-3 at position D393.

We finally investigated whether in vivo CASP-1 itself is required for TNF-induced cleavage of PITSLRE kinases; thus we analyzed the effect of TNF in embryonic fibroblasts obtained from CASP-10/0 mice (27, 28). As shown in Fig. 5, TNF-induced cell death and PITSLRE kinase cleavage was similar in wild-type and CASP-1-deficient fibroblasts. Taking into account that CASP-3 was the only other CASP that was found to cleave p110 PITSLRE kinase in vitro, the above results suggest a crucial role for CASP-3-mediated cleavage of PITSLRE kinases in the TNF-induced cell death pathway. We cannot, however, exclude an involvement of other newly identified (CASP-8, CASP-9, CASP-10; Refs. 21-24) or still unidentified CASPs (although the inhibition by CrmA limits possible candidates), or a more complex scenario involving two or more proteases which function redundantly or concomitantly, such that elimination of CASP-1 alone has no effect. The biological implication for CASP-3-mediated cleavage of PITSLRE kinases in TNF-induced apoptosis is still unclear. To date, no specific substrates for PITSLRE kinases have been identified. Cleavage by CASP-1 and CASP-3 occurs at a site that separates the C-terminal kinase domain from the N-terminal part that harbors two nuclear localization signals as well as a region that has been shown to bind SH2 domains (29). Therefore, CASP-3-mediated cleavage of PITSLRE kinases might be a mechanism to modulate their localization or interaction with other proteins. It should also be mentioned that in addition to PITSLRE kinases, Cdc2 itself and other Cdc2-like enzymes have been shown to play a role in apoptosis induced by TNF and granzyme B (30, 31).


Fig. 5. Cleavage of PITSLRE kinases in CASP-1-deficient cells. Primary embryonic fibroblasts from wild-type (CASP-1+/+) or CASP-10/0 mice (CASP-1-/-) were either left untreated or treated with 10,000 IU ml-1 human TNF in the presence of 0.1 µg ml-1 actinomycin D for 8 h. Expression and cleavage of PITSLRE kinases was assessed by Western blotting with P2N100 (A) and GN1 (B) antibodies, respectively. Cell death is indicated at the bottom of each lane and represents the mean of triplicate samples with an S.D. <10%.
[View Larger Version of this Image (34K GIF file)]

In conclusion, we have shown that TNF-induced apoptosis is associated with CASP-3-specific proteolysis of PITSLRE kinases. This processing does not occur in cells in which the apoptotic pathway is blocked by Bcl-2 or by CrmA expression. Since the PITSLRE kinases represent the first CASP substrates for which a direct apoptotic function and a role in tumorigenesis have been described (5-10), our findings might have important implications for understanding the mechanism of action of TNF, as well as the regulation of apoptosis in human cancer and other diseases.


FOOTNOTES

*   This work was supported by the Interuniversitaire Attractiepolen, the Fonds voor Geneeskundig Wetenschappelijk Onderzoek, the Vlaams Interuniversitair Instituut voor Biotechnologie, EC Biotech Program Grant BIO2-CT92-0316, EC Biomed Program Grant BMH4-CT96-0300, National Institutes of Health Grant GM44088, Cancer Center Core Grant CA21765, and by the American Lebanese Syrian Associated Charities (ALSAC).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Postdoctoral Fellow with the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen.
   Research Assistant with the Fonds voor Wetenschappelijk Onderzoek-Vlaanderen.
par    To whom correspondence should be addressed: Laboratory of Molecular Biology, K. L. Ledeganckstraat 35, B-9000 Ghent, Belgium. Tel.: 32-9-264-51-31; Fax: 32-9-264-53-48; E-mail: fiers{at}lmb1.rug.ac.be.
1   The abbreviations used are: ICE, interleukin-1beta -converting enzyme; AMC, aminomethylcoumarin; CASP, caspase; IL-1beta , interleukin-1beta ; TNF, tumor necrosis factor; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction.
2   R. Gururajan and V. J. Kidd, unpublished data.

ACKNOWLEDGEMENTS

We thank Drs. N. Thornberry and R. Talanian for recombinant human ICE, Dr. D. Pickup for crmA cDNA, as well as Dr. R. Kamen and Dr. T. Seshadri for ICE0/0 mice and Ilse Van den brande for expression and purification of CASPs.


REFERENCES

  1. Thompson, C. B. (1995) Science 267, 1456-1462 [Medline] [Order article via Infotrieve]
  2. Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., and Yuan, J. (1996) Cell 87, 171 [Medline] [Order article via Infotrieve]
  3. Fraser, A., and Evan, G. (1996) Cell 85, 781-784 [Medline] [Order article via Infotrieve]
  4. Henkart, P. A. (1996) Immunity 4, 195-201 [Medline] [Order article via Infotrieve]
  5. Bunnell, B. A., Heath, L. S., Adams, D. E., Lahti, J. M., and Kidd, V. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7467-7471 [Abstract]
  6. Xiang, J., Lahti, J. M., Grenet, J., Easton, J., and Kidd, V. J. (1994) J. Biol. Chem. 269, 15786-15794 [Abstract/Free Full Text]
  7. Lahti, J. M., Xiang, J., Heath, L. S., Campana, D., and Kidd, V. J. (1995) Mol. Cell. Biol. 15, 1-11 [Abstract]
  8. Lahti, J. M., Valentine, M., Xiang, J., Jones, B., Amann, J., Grenet, J., Richmond, G., Look, A. T., and Kidd, V. J. (1994) Nat. Genet. 7, 370-375 [Medline] [Order article via Infotrieve]
  9. Bishop, J. M. (1991) Cell 64, 235-248 [Medline] [Order article via Infotrieve]
  10. Takeda, O., Homma, C., Maseki, N., Sakurai, M., Kanda, N., Scwab, M., Nakamura, Y., and Kaneko, Y. (1994) Genes Chromosomes Cancer 10, 30-39 [Medline] [Order article via Infotrieve]
  11. Vandenabeele, P., Declercq, W., Vanhaesebroeck, B., Grooten, J., and Fiers, W. (1995) J. Immunol. 154, 2904-2913 [Abstract/Free Full Text]
  12. Ray, C. A., Black, R. A., Kronheim, S. R., Greenstreet, T. A., Sleath, P. R., Slavesen, G. S., and Pickup, D. J. (1992) Cell 69, 597-604 [Medline] [Order article via Infotrieve]
  13. Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Gene (Amst.) 108, 193-200 [CrossRef][Medline] [Order article via Infotrieve]
  14. Suffys, P., Beyaert, R., Van Roy, F., and Fiers, W. (1989) Anticancer Res. 9, 167-172 [Medline] [Order article via Infotrieve]
  15. Tada, H., Shiho, O., Kuroshima, K., Koyama, M., and Tsukamoto, K. (1986) J. Immunol. Methods 93, 157-165 [CrossRef][Medline] [Order article via Infotrieve]
  16. Van de Craen, M., Vandenabeele, P., Declercq, W., Van den brande, I., Van Loo, G., Molemans, F., Schotte, P., Van Criekinge, W., Beyaert, R., and Fiers, W. (1997) FEBS Lett. 403, 61-69 [CrossRef][Medline] [Order article via Infotrieve]
  17. Mertens, N., Remaut, E., and Fiers, W. (1995) Gene (Amst.) 164, 9-15 [CrossRef][Medline] [Order article via Infotrieve]
  18. Chinnaiyan, A. M., Orth, K., O'Rourke, K., Duan, H., Poirier, G. G., and Dixit, V. M. (1996) J. Biol. Chem. 271, 4573-4576 [Abstract/Free Full Text]
  19. Tewari, M., and Dixit, V. M. (1995) J. Biol. Chem. 270, 3255-3260 [Abstract/Free Full Text]
  20. Miura, M., Friedlander, R. M., and Yuan, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8318-8322 [Abstract]
  21. Fernandes-Alnemri, T., Armstrong, R. C., Krebs, J., Srinivasa, S. M., Wang, L., Bullrich, F., Fritz, L. C., Trapani, J. A., Tomaselli, K. J., Litwack, G., and Alnemri, E. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7464-7469 [Abstract/Free Full Text]
  22. Boldin, M. P., Goncharov, T. M., Goltsev, Y. V., and Wallach, D. (1996) Cell 85, 803-815 [Medline] [Order article via Infotrieve]
  23. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. (1996) Cell 85, 817-827 [Medline] [Order article via Infotrieve]
  24. Duan, H., Orth, K., Chinnaiyan, A. M., Poirier, G. G., Froelich, C. J., He, W.-W., and Dixit, V. M. (1996) J. Biol. Chem. 271, 16720-16724 [Abstract/Free Full Text]
  25. Wang, S., Miura, M., Jung, Y., Zhu, H., Gagliardini, V., Shi, L., Greenberg, A. H., and Yuan, J. (1996) J. Biol. Chem. 271, 20580-20587 [Abstract/Free Full Text]
  26. Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., Elliston, K. O., Ayalal, J. M., Casano, F. J., Chin, J., Ding, G. J. F., Egger, L. A., Gaffney, E. P., Limjuco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, J. P., Yamin, T.-T., Lee, T. D., Shively, J. E., MacCross, M., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1992) Nature 356, 768-774 [CrossRef][Medline] [Order article via Infotrieve]
  27. Kuida, K., Lippke, J. A., Ku, G., Harding, M. W., Livingston, D. J., Su, M. S.-S., and Flavell, R. A. (1995) Science 267, 2000-2003 [Medline] [Order article via Infotrieve]
  28. Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C., McDowell, J., Paskind, M., Rodman, L., Salfeld, J., Towne, E., Tracey, D., Wardwell, S., Wei, F., Wong, W., Kamen, R., and Seshadri, T. (1995) Cell 80, 401-411 [Medline] [Order article via Infotrieve]
  29. Malek, S. N., and Desiderio, S. (1994) J. Biol. Chem. 269, 33009-33020 [Abstract/Free Full Text]
  30. Meikrantz, W., and Schlegel, R. (1996) J. Biol. Chem. 271, 10205-10209 [Abstract/Free Full Text]
  31. Shi, L., Nishioka, W. K., Th'ng, J., Bradbury, E. M., Litchfield, D. W., and Greenberg, A. H. (1994) Science 263, 1143-1145 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.